产品
编 号：F744933
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1418200-58-4
产品详情
生物活性：
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.
体内研究：
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) 在 MUC16 表达的人 OVCAR-3 小鼠异种移植物模型中显示出强大的抗肿瘤活性。Animal Model:Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts
Dosage:2.8 mg/kg
Administration:IV, once weekly for 4 total doses
Result:Improved survival.
Animal Model:Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads
Dosage:2 mg/kg
Administration:IV, once weekly for 3 total doses
Result:Significantly decreased the tumor volume.
体外研究：
Sofituzumab vedotin (DMUC5754A) 是一种抗体-药物偶联物 (ADC)，包含人源化 IgG1 抗 MUC16 单克隆抗体和一种有效的抗有丝分裂剂 MMAE，通过蛋白酶不稳定的连接子 maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl 连接。Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) 以剂量依赖方式抑制 OVCAR-3 和 PC3/MUC16TMlong 细胞增殖。
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.
体内研究：
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) 在 MUC16 表达的人 OVCAR-3 小鼠异种移植物模型中显示出强大的抗肿瘤活性。Animal Model:Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts
Dosage:2.8 mg/kg
Administration:IV, once weekly for 4 total doses
Result:Improved survival.
Animal Model:Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads
Dosage:2 mg/kg
Administration:IV, once weekly for 3 total doses
Result:Significantly decreased the tumor volume.
体外研究：
Sofituzumab vedotin (DMUC5754A) 是一种抗体-药物偶联物 (ADC)，包含人源化 IgG1 抗 MUC16 单克隆抗体和一种有效的抗有丝分裂剂 MMAE，通过蛋白酶不稳定的连接子 maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl 连接。Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) 以剂量依赖方式抑制 OVCAR-3 和 PC3/MUC16TMlong 细胞增殖。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备